Takeda Pharma 9-month Profit, Revenue Rise; Ups Annual Outlook

Takeda Pharmaceutical Company Limited (TKPHF.PK) on Thursday reported net profit of 241.42 billion yen or 153.03 yen per share for the 9-month period, 34.9% higher than 178.91 billion yen or 113.72 yen per share in the same period a year ago, helped by higher revenue

Profit before tax rose to 356.62 billion yen from 235.36 billion last year.

Core EPS for the 9-month period was 333 yen.

The company's revenue for the period increased 11% year-over-year to 2,695.72 billion yen from 2,427.54 billion yen.

The company has raised its full-year revenue as well as EPS outlook. Revenue is now seen at 3,510 billion yen for the full-year, up from 3,370 billion yen as guided in October last year. Core EPS forecast has been raised to 416 yen from 394 yen.

"We remain committed to growing revenue over the next decade through continued investment in our 14 global brands and our innovative pipeline of approximately 40 clinical-stage assets, which is already starting to deliver with the recent launch in the U.S. of LIVTENCITY, the second major regulatory approval for our pipeline in FY2021 after EXKIVITY," Costa Saroukos, Chief Financial Officer commented.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT